1. Transforming growth factor-β induces microRNA-29b to promote murine alveolar macrophage dysfunction after bone marrow transplantation
- Author
-
Jeanette P. Brown, Yasmina Laouar, Gregory A. Yanik, Christine M. Freeman, Racquel Domingo-Gonzalez, Steven K. Huang, Carol A. Wilke, Jeffrey L. Curtis, and Bethany B. Moore
- Subjects
Pulmonary and Respiratory Medicine ,Adult ,Male ,Methyltransferase ,Physiology ,medicine.medical_treatment ,Hematopoietic stem cell transplantation ,Biology ,Dinoprostone ,Mice ,Downregulation and upregulation ,Transforming Growth Factor beta ,Physiology (medical) ,microRNA ,Macrophages, Alveolar ,medicine ,Animals ,Humans ,DNA (Cytosine-5-)-Methyltransferases ,Prostaglandin E2 ,Bone Marrow Transplantation ,Hematopoietic Stem Cell Transplantation ,Cell Biology ,Transfection ,Articles ,DNA Methylation ,Middle Aged ,Allografts ,MicroRNAs ,surgical procedures, operative ,Cyclooxygenase 2 ,Immunology ,Cancer research ,Alveolar macrophage ,Female ,Transforming growth factor ,medicine.drug ,Signal Transduction - Abstract
Hematopoietic stem cell transplantation (HSCT) is complicated by pulmonary infections that manifest posttransplantation. Despite engraftment, susceptibility to infections persists long after reconstitution. Previous work using a murine bone marrow transplant (BMT) model implicated increased cyclooxygenase-2 (COX-2) and prostaglandin E2(PGE2) in promoting impaired alveolar macrophage (AM) responses. However, mechanisms driving COX-2 overexpression remained elusive. Previously, transforming growth factor-β (TGF-β) signaling after BMT was shown to promote hypomethylation of the COX-2 gene. Here, we provide mechanistic insight into how this occurs and show that TGF-β induces microRNA (miR)-29b while decreasing DNA methyltransferases (DNMT)1, DNMT3a, and DNMT3b in AMs after BMT. De novo DNMT3a and DNMT3b were decreased upon transient transfection of miR-29b, resulting in decreased methylation of the COX-2 promoter and induction of COX-2. As a consequence, miR-29b-driven upregulation of COX-2 promoted AM dysfunction, and transfection of BMT AMs with a miR-29b inhibitor rescued the bacterial-killing defect. MiR-29b-mediated defects in BMT AMs were dependent on increased levels of PGE2, as miR-29b-transfected AMs treated with a novel E prostanoid receptor 2 antagonist abrogated the impaired bacterial killing. We also demonstrate that patients that have undergone HSCT exhibit increased miR-29b; thus these studies highlight miR-29b in driving defective AM responses and identify this miRNA as a potential therapeutic target.
- Published
- 2014